nach oben

Current Gastroenterology Reports

Erschienen in:

01.12.2020 | Endoscopy and Surgery (S Komanduri, Section Editor)

Endoscopic Eradication Therapy for Barrett’s Neoplasia: Where Do We Stand a Decade Later?

verfasst von: Blake Jones, Sachin Wani

Erschienen in: Current Gastroenterology Reports | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Barrett’s esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a cancer associated with increasing incidence and poor survival. Early identification and effective treatment of BE-related neoplasia prior to the development of invasive adenocarcinoma are essential to limiting the morbidity and mortality associated with this cancer. In this review, we summarized the recent evidence guiding endoscopic eradication therapies (EET) for neoplastic BE.

Recent Findings

New sampling technologies and the application of artificial intelligence (AI) systems have potential to revolutionize early neoplasia detection in BE. EET for BE are safe and effective in achieving complete eradication of intestinal metaplasia (CE-IM) and reducing the progression to EAC, a practice endorsed by all GI society guidelines. EET should be considered in patients with high-grade dysplasia (HGD), intramucosal carcinoma (IMC), and select cases with low-grade dysplasia (LGD). The increasing use of endoscopic submucosal dissection (ESD) in the West may allow EET of select cases with submucosal EAC. Post-EET surveillance strategies will continue to evolve as knowledge of specific risk factors and long-term neoplasia recurrence rates improve.

Summary

In the last decade, major advancements in EET for neoplastic BE have been achieved. These now represent the standard of care in the management of BE-related dysplasia and intramucosal cancer.

Coleman HG, Xie S-H, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 2018;154(2):390–405.PubMed

Ilson DH, van Hillegersberg R. Management of patients with adenocarcinoma or squamous cancer of the esophagus. Gastroenterology. 2018;154(2):437–51.PubMed

Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol. 2011;26(9):739–45.PubMed

Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in the Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007;42(1):17–22.PubMed

Rubenstein JH, Mattek N, Eisen G. Age- and sex-specific yield of Barrett’s esophagus by endoscopy indication. Gastrointest Endosc. 2010;71(1):21–7.PubMed

Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med. 2014;371(9):836–45.PubMed

Hammad T, Thrift A, El-Serag H, Husain N. Missed opportunities for screening and surveillance of Barrett’s esophagus in veterans with esophageal adenocarcinoma. Dig Dis Sci. 2019;64(2):367–72.PubMed

Nicholas SJ, Gary FW, Prasad IG, Lauren GB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50.

Fock KM, Talley N, Goh KL, Sugano K, Katelaris P, Holtmann G, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65(9):1402–14015.PubMed

10.

Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau J-M, Esteban J-M, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49(2):191–8.PubMed

11.

Wani S, Qumseya B, Sultan S, Agrawal D, Chandrasekhara V, Harnke B, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus–associated dysplasia and intramucosal cancer. Standards of Practice Committee, editor. Gastrointest Endosc. 2018;87(4):907–931.e9.PubMed

12.•

Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. ASGE Standards Of Practice Committee, ASGE Standards of Practice Committee Chair, editors. Gastrointest Endosc. 2019;90(3):335–359.e2 Most up-to-date ASGE guidelines based on systemic review and meta-analysis. Including recommendations touching on screening and surveillance in BE, as well as input on new technologies like VLE and WATS.PubMed

13.

Wani S, Drahos J, Cook MB, Rastogi A, Bansal A, Yen R, et al. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. Gastrointest Endosc. 2014;79(2):224–232.e1.PubMed

14.

Lockwood R, Ozanne E, Hur C, Yachimski P. Patient decision-making and clinical outcomes following endoscopic therapy or esophagectomy for Barrett’s neoplasia. Endosc Int Open. 2017;5(11):E1128–35.PubMedPubMedCentral

15.

Li C, Yamashita D, Hawel J, Bethune D, Henteleff H, Ellsmere J. Endoscopic mucosal resection versus esophagectomy for intramucosal adenocarcinoma in the setting of Barrett’s esophagus. Surg Endosc. 2017;31(10):4211–6.PubMed

16.

Inadomi J, Saxena N. Screening and surveillance for Barrett’s esophagus: is it cost-effective? Dig Dis Sci. 2018;63(8):2094–104.PubMed

17.

Fitzgerald, Rebecca, di Pietro, Massimiliano, Ragunath, Krish, Ang, Yeng, Kang, Jin-Yong, Watson, Peter, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. 2014.

18.

Abela J-E, Going JJ, Mackenzie JF, McKernan M, O’Mahoney S, Stuart RC. Systematic four-quadrant biopsy detects Barrett’s dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol. 2008;103(4):850–5 Available from: https://journals.lww.com/ajg/Fulltext/2008/04000/Systematic_Four_Quadrant_Biopsy_Detects_Barrett_s.7.aspx.PubMed

19.

Sharma P, Dent J, Armstrong D, Bergman JJGHM, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M Criteria. Gastroenterology. 2006;131(5):1392–9.PubMed

20.

Lambert R, Sharma P. Paris workshop on columnar metaplasia in the esophagus and the esophagogastric junction, Paris, France, December 11-12 2004. Endoscopy. 2005;37(9):879.

21.

Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76(3):531–8.PubMed

22.

Wani S, Gaddam S. Editorial: best practices in surveillance of Barrettʼs esophagus. Am J Gastroenterol. 2017;112(7):1056–60.PubMed

23.

Codipilly DC, Chandar AK, Singh S, Wani S, Shaheen NJ, Inadomi JM, et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. Gastroenterology. 2018;154(8):2068–2086.e5.PubMedPubMedCentral

24.

Wani S, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Endoscopists systematically undersample patients with long-segment Barrett’s esophagus: an analysis of biopsy sampling practices from a quality improvement registry. Gastrointest Endosc. 2019;90(5):732–741.e3.PubMed

25.••

Parasa S, Desai M, Vittal A, Chandrasekar VT, Pervez A, Kennedy KF, et al. Estimating neoplasia detection rate (NDR) in patients with Barrett’s oesophagus based on index endoscopy: a systematic review and meta-analysis. Gut. 2019;68(12):2122–8 A recent systemic review and meta-analysis proposing a new quality indicator in BE-labeled neoplasia detection rate. This QI has the potential to contribute a valuable new benchmark to assess high value care delivery in BE (similar to the ADR in colonoscopy), though it requires further study to demonstrate correlation with important clinical outcomes.PubMed

26.

Jones B, Wani S. Catching up to the colon: time for an adenoma detection rate equivalent in Barrett’s esophagus? Gastroenterology. 2020;158(3):791–2.PubMed

27.

Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2016;150(3):599–607.e7.PubMed

28.

Wani S, Gyawali CP, Katzka DA. AGA clinical practice update on reducing rates of post endoscopy esophageal adenocarcinoma: commentary. Gastroenterol. 2020;159(4):1533–7 Epub ahead of print.

29.

Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neugut AI, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7(7):736–42.PubMedPubMedCentral

30.

31.•

Smith MS, Ikonomi E, Bhuta R, Iorio N, Kataria RD, Kaul V, et al. Wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS) markedly improves detection of esophageal dysplasia and Barrett’s esophagus: analysis from a prospective multicenter community-based study. Dis Esophagus. 2018;32(3):doy099 Real world, prospective, multi-center study evaluating WATS, a new technology that has potential to significantly change dysplasia detection in BE. Further research is needed in order to assess cost-effectiveness and better understand how to address increasing diagnosis of LGD or IND if widely implemented.PubMedCentral

32.

Hashimoto R, Requa J, Dao T, Ninh A, Tran E, Mai D, et al. Artificial intelligence using convolutional neural networks for real-time detection of early esophageal neoplasia in Barrett’s esophagus (with video). Gastrointest Endosc. 2020;91:1264–1271.e1.PubMed

33.

de Groof AJ, Struyvenberg MR, van Der Putten J, van Der Sommen F, Fockens KN, Curvers WL, et al. Deep-learning system detects neoplasia in patients with Barrett’s esophagus with higher accuracy than endoscopists in a multistep training and validation study with benchmarking. Gastroenterology. 2020;158(4):915–929.e4.PubMed

34.••

de Groof AJ, Struyvenberg MR, Fockens KN, van der Putten J, van der Sommen F, Boers TG, et al. Deep learning algorithm detection of Barrett’s neoplasia with high accuracy during live endoscopic procedures: a pilot study (with video). Gastrointest Endosc. 2020;91(6):1242–50 One of the first real-world demonstrations of artificial intelligence–aided diagnosis of neoplasia in BE. Use of AI in endoscopy is likely to become more widely available in the coming years and has potential to significantly improve endoscopists’ ability to detect endoscopically apparent BE-related neoplasia.PubMed

35.

Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology. 2016;151(5):822–35.PubMed

36.

Konda V, Souza R. Biomarkers of Barrett’s esophagus: from the laboratory to clinical practice. Dig Dis Sci. 2018;63(8):2070–80.PubMedPubMedCentral

37.

El-Serag HB, Naik AD, Duan Z, Shakhatreh M, Helm A, Pathak A, et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut. 2016;65(8):1252–60.PubMed

38.

Angela TC, Deirdre SF, Jennifer YM, Chung KY, Emily DC, Joel RH, et al. The impact of a prior diagnosis of Barrett’s esophagus on esophageal adenocarcinoma survival. Am J Gastroenterol. 2017;112(8):1256–64.

39.

Wani S, Puli SR, Shaheen NJ, Westhoff B, Slehria S, Bansal A, et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol. 2009;104(2):502–13.PubMed

40.

Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143(3):567–75.PubMedPubMedCentral

41.

Das A, Callenberg K, Styn M, Jackson S. Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett’s esophagus who have elevated genomic instability. Endosc Int Open. 2016;4(5):E549–59.PubMedPubMedCentral

42.

Pollit V, Graham D, Leonard C, Filby A, Mcmaster J, Mealing SJ, et al. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett’s oesophagus in the United Kingdom. Curr Med Res Opin. 2019;35(5):805–15.PubMed

43.

Omidvari A-H, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, et al. Optimizing management of patients with Barrett’s esophagus and low-grade or no dysplasia based on comparative modeling. Clin Gastroenterol Hepatol. 2019;18(9):1961–9.PubMed

44.

Duits LC, Phoa KN, Curvers WL, ten Kate FJW, Meijer GA, Seldenrijk CA, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700–6.PubMed

45.

Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–30 Available from: https://journals.lww.com/ajg/Fulltext/2010/07000/Low_Grade_Dysplasia_in_Barrett_s_Esophagus_.14.aspx.PubMed

46.•

Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. AGA Clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and/or early cancer: expert review. Gastroenterology. 2020;158(3):760–9 The AGA guidelines, updated this year, discuss the most recent evidence guiding use of various EET including ESD, as well as the evidence for post-EET surveillance.PubMed

47.

Othman MO, Lee JH, Wang K. AGA clinical practice update on the utility of endoscopic submucosal dissection in T1b esophageal cancer: expert review. Clin Gastroenterol Hepatol. 2019;17(11):2161–6.PubMed

48.

Sachin WV, Raman MJ, Nicholas SA, Rena YA, Robert WW, Julian AM, et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) consortium. Am J Gastroenterol. 2017;112(7):1032–48.

49.

Mohan BP, Krishnamoorthi R, Ponnada S, Shakhatreh M, Jayaraj M, Garg R, et al. Liquid nitrogen spray cryotherapy in treatment of Barrett’s esophagus, where do we stand? A Systematic Review and Meta-Analysis. Dis Esophagus. 2019;32(6):doy130.PubMed

50.

Visrodia K, Zakko L, Wang K. Mucosal ablation in patients with Barrett’s esophagus: fry or freeze? Dig Dis Sci. 2018;63(8):2129–35.PubMed

51.

Spiceland C, Elmunzer B, Paros S, Roof L, McVey M, Hawes R, et al. Salvage cryotherapy in patients undergoing endoscopic eradication therapy for complicated Barrett’s esophagus. Endosc Int Open. 2019;7(7):E904–11.PubMedPubMedCentral

52.

Visrodia K, Zakko L, Singh S, Leggett CL, Iyer PG, Wang KK. Cryotherapy for persistent Barrett’s esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointest Endosc. 2018;87(6):1396–1404.e1.PubMedPubMedCentral

53.

Ghorbani S, Tsai FC, Greenwald BD, Jang S, Dumot JA, Mckinley MJ, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s dysplasia: results of the National Cryospray Registry. Dis Esophagus. 2016;29(3):241–7.PubMed

54.

Canto MI, Shaheen NJ, Almario JA, Voltaggio L, Montgomery E, Lightdale CJ. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus (with video). Gastrointest Endosc. 2018;88(3):438–446.e2.PubMed

55.

van Munster SN, Overwater A, Raicu MGM, Seldenrijk KCA, Nagengast WB, Schoon EJ, et al. A novel cryoballoon ablation system for eradication of dysplastic Barrett’s esophagus: a first-in-human feasibility study. Endoscopy. 2019;52(3):193–201.PubMed

56.

Peerally MF, Bhandari P, Ragunath K, Barr H, Stokes C, Haidry R, et al. Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett’s esophagus: a randomized pilot study (BRIDE). Gastrointest Endosc. 2019;89(4):680–9.PubMed

57.

Aranda-Hernández J, Shimamura Y, Grin A, Iwaya Y, Cirocco M, Kandel G, et al. Hot avulsion may be effective as salvage treatment for focal Barrett’s esophagus remaining after endoscopic therapy for dysplasia or early cancer: a preliminary study. Endoscopy. 2018;50(1):8–13.PubMed

58.

Nieto J, Casas D. 935 Salvage hybrid APC after failed radiofrequency ablation and cryotherapy for Barrett’s esophagus. Am J Gastroenterol. 2019;114(1):S544–5.

59.

Terheggen G, Horn EM, Vieth M, Gabbert H, Enderle M, Neugebauer A, et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett’s neoplasia. Gut. 2017 May 1;66(5):783–93.PubMed

60.••

Yang D, Zou F, Xiong S, Forde JJ, Wang Y, Draganov PV. Endoscopic submucosal dissection for early Barrett’s neoplasia: a meta-analysis. Gastrointest Endosc. 2018;87(6):1383–93 A recent meta-analysis that demonstrated feasibility and relative success and low AE among patients undergoing ESD for early EAC. This study included data from both Asian and North American and European populations, which is important given the early adoption of ESD (and thus greater expertise) in the East compared to the West.PubMed

61.

Yang D, Othman M, Draganov PV. Endoscopic mucosal resection vs endoscopic submucosal dissection for Barrett’s esophagus and colorectal neoplasia. Clin Gastroenterol Hepatol. 2019;17(6):1019–28.PubMed

62.

Draganov PV, Wang AY, Othman MO, Fukami N. AGA Institute clinical practice update: endoscopic submucosal dissection in the United States. Clin Gastroenterol Hepatol. 2019;17(1):16–25.e1.PubMed

63.

Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(10):1245–55.PubMed

64.

Tarek SG, Prasad IC, Mouaz AL, Cary CM, Cadman LK, Hassan MJ, et al. Higher rate of Barrettʼs detection in the first year after successful endoscopic therapy: meta-analysis. Am J Gastroenterol. 2018;113(7):959–71.

65.

Kahn A, Shaheen NJ, Iyer PG. Approach to the post-ablation Barrett’s esophagus patient. Am J Gastroenterol. 2020;00:1–9.

66.••

Cotton CC, Haidry R, Thrift AP, Lovat L, Shaheen NJ. Development of evidence-based surveillance intervals after radiofrequency ablation of Barrett’s esophagus. Gastroenterology. 2018;155(2):316–326.e6 Modeling study based on US and UK registries that attempted to determine the correct surveillance intervals after EET in BE. The proposed intervals developed in this study are now widely recommended in society guidelines.PubMedPubMedCentral

67.

Soroush A, Poneros JM, Lightdale CJ, Abrams JA. Shorter time to achieve endoscopic eradication is not associated with improved long-term outcomes in Barrett’s esophagus. Dis Esophagus. 2019;32(8):doz026.PubMed

68.

Tan MC, Kanthasamy KA, Yeh AG, Kil D, Pompeii L, Yu X, et al. Factors associated with recurrence of Barrett’s esophagus after radiofrequency ablation. Clin Gastroenterol Hepatol. 2019;17(1):65–72.e5.PubMed

69.

Wani S, Han S, Kushnir V, Early D, Mullady D, Hammad H, et al. Recurrence is rare following complete eradication of intestinal metaplasia in patients with Barrett’s esophagus and peaks at 18 months. Clin Gastroenterol Hepatol. 2020;18(11):2609–17.PubMed

70.

Cotton CC, Wolf WA, Overholt BF, Li N, Lightdale CJ, Wolfsen HC, et al. Late recurrence of Barrett’s esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. AIM Dysplasia Trial Group, editor. Gastroenterology. 2017;153(3):681–688.e2.PubMedPubMedCentral

71.

Sami S, Ravindran A, Kahn A, Snyder D, Santiago J, Ortiz-Fernandez-Sordo J, et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut. 2019;68:1379–85.PubMed

72.

Omar M, Thaker AM, Wani S, Simon V, Ezekwe E, Boniface M, et al. Anatomic location of Barrett’s esophagus recurrence after endoscopic eradication therapy: development of a simplified surveillance biopsy strategy. Gastrointest Endosc. 2019;90(3):395–403.PubMed

Titel: Endoscopic Eradication Therapy for Barrett’s Neoplasia: Where Do We Stand a Decade Later?
verfasst von: Blake Jones
Sachin Wani
Publikationsdatum: 01.12.2020
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 12/2020
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-020-00799-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Determining the Indeterminate Biliary Stricture: Cholangioscopy and Beyond

Advances in Biliary Access

Emerging Therapies to Prevent Post-ERCP Pancreatitis

Causes and Management of Non-cirrhotic Portal Hypertension​

Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota

Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?